127 related articles for article (PubMed ID: 25510697)
1. Serum microRNAs in clear cell carcinoma of the ovary.
Chao A; Lai CH; Chen HC; Lin CY; Tsai CL; Tang YH; Huang HJ; Lin CT; Chen MY; Huang KG; Chou HH; Chang TC; Chen SJ; Wang TH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):536-41. PubMed ID: 25510697
[TBL] [Abstract][Full Text] [Related]
2. Primary analysis and screening of microRNAs in gastric cancer side population cells.
Zhang HH; Gu GL; Zhang XY; Li FZ; Ding L; Fan Q; Wu R; Shi W; Wang XY; Chen L; Wei XM; Yuan XY
World J Gastroenterol; 2015 Mar; 21(12):3519-26. PubMed ID: 25834316
[TBL] [Abstract][Full Text] [Related]
3. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
4. Expression of microRNAs in basal cell carcinoma.
Sand M; Skrygan M; Sand D; Georgas D; Hahn SA; Gambichler T; Altmeyer P; Bechara FG
Br J Dermatol; 2012 Oct; 167(4):847-55. PubMed ID: 22540308
[TBL] [Abstract][Full Text] [Related]
5. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer.
Günel T; Gumusoglu E; Dogan B; Ertem FB; Hosseini MK; Cevik N; Senol T; Topuz S; Aydinli K
Arch Gynecol Obstet; 2018 Dec; 298(6):1173-1180. PubMed ID: 30264202
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of reference genes for the detection of serum microRNAs by reverse transcription-quantitative polymerase chain reaction in patients with bladder cancer.
Wang L; Liu Y; Du L; Li J; Jiang X; Zheng G; Qu A; Wang H; Wang L; Zhang X; Liu H; Pan H; Yang Y; Wang C
Mol Med Rep; 2015 Jul; 12(1):615-22. PubMed ID: 25738263
[TBL] [Abstract][Full Text] [Related]
7. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform.
Resnick KE; Alder H; Hagan JP; Richardson DL; Croce CM; Cohn DE
Gynecol Oncol; 2009 Jan; 112(1):55-9. PubMed ID: 18954897
[TBL] [Abstract][Full Text] [Related]
8. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma.
Schaefer A; Jung M; Mollenkopf HJ; Wagner I; Stephan C; Jentzmik F; Miller K; Lein M; Kristiansen G; Jung K
Int J Cancer; 2010 Mar; 126(5):1166-76. PubMed ID: 19676045
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of serum microRNA-21 in colorectal cancer.
Menéndez P; Padilla D; Villarejo P; Palomino T; Nieto P; Menéndez JM; Rodríguez-Montes JA
J Surg Oncol; 2013 Nov; 108(6):369-73. PubMed ID: 23970420
[TBL] [Abstract][Full Text] [Related]
11. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of esophageal squamous cell carcinoma.
Yang M; Liu R; Sheng J; Liao J; Wang Y; Pan E; Guo W; Pu Y; Yin L
Oncol Rep; 2013 Jan; 29(1):169-76. PubMed ID: 23124769
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
13. Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma.
Sand M; Skrygan M; Georgas D; Sand D; Hahn SA; Gambichler T; Altmeyer P; Bechara FG
J Dermatol Sci; 2012 Dec; 68(3):119-26. PubMed ID: 23026055
[TBL] [Abstract][Full Text] [Related]
14. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma.
Hauser S; Wulfken LM; Holdenrieder S; Moritz R; Ohlmann CH; Jung V; Becker F; Herrmann E; Walgenbach-Brünagel G; von Ruecker A; Müller SC; Ellinger J
Cancer Epidemiol; 2012 Aug; 36(4):391-4. PubMed ID: 22542158
[TBL] [Abstract][Full Text] [Related]
15. MiR-142-3p as a potential prognostic biomarker for esophageal squamous cell carcinoma.
Lin RJ; Xiao DW; Liao LD; Chen T; Xie ZF; Huang WZ; Wang WS; Jiang TF; Wu BL; Li EM; Xu LY
J Surg Oncol; 2012 Feb; 105(2):175-82. PubMed ID: 21882196
[TBL] [Abstract][Full Text] [Related]
16. microRNA portraits in human vulvar carcinoma.
de Melo Maia B; Lavorato-Rocha AM; Rodrigues LS; Coutinho-Camillo CM; Baiocchi G; Stiepcich MM; Puga R; de A Lima L; Soares FA; Rocha RM
Cancer Prev Res (Phila); 2013 Nov; 6(11):1231-41. PubMed ID: 24048714
[TBL] [Abstract][Full Text] [Related]
17. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
18. miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma.
Kim TH; Song JY; Park H; Jeong JY; Kwon AY; Heo JH; Kang H; Kim G; An HJ
Cancer Lett; 2015 Jan; 356(2 Pt B):937-45. PubMed ID: 25444913
[TBL] [Abstract][Full Text] [Related]
19. Serum miR-1181 and miR-4314 associated with ovarian cancer: MiRNA microarray data analysis for a pilot study.
Ruan L; Xie Y; Liu F; Chen X
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():31-38. PubMed ID: 29353130
[TBL] [Abstract][Full Text] [Related]
20. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma.
Iwamoto H; Kanda Y; Sejima T; Osaki M; Okada F; Takenaka A
Int J Oncol; 2014 Jan; 44(1):53-8. PubMed ID: 24212760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
